ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
124.612,22
-1,13%
S&P 500
6.051,09
0,00%
US Dollar vs BRL
6,0424
0,00%
Bitcoin
101.524,32
0,07%
Brent Oil
74,135
0,00%
As Melhores Corretoras Online
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Innate Pharma SA (IPHA)

  7. Innate Pharma SA (IPHA) Notícias

IPHA

Innate Pharma (IPHA)

Innate Pharma SA
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:IPHA
DataHoraFonteTítuloCódigoCompanhia
09/12/202408:04Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPHAInnate Pharma SA
09/12/202403:00Business WireInnate Pharma présente à l’ASH 2024 des données de l’étude de Phase 2 TELLOMAK sur l’amélioration de la qualité de vie chez des patients atteints de lymphomes T cutanésNASDAQ:IPHAInnate Pharma SA
09/12/202403:00Business WireInnate Pharma Presents Lacutamab Improved Health-related Quality of Life Data at ASH 2024 From TELLOMAK Phase 2 Study in Patients With Cutaneous T Cell LymphomaNASDAQ:IPHAInnate Pharma SA
06/12/202403:00Business WireInnate Pharma et l’Institut d’Innovation pour le Lymphome Folliculaire (IFLI) annoncent un investissement jusqu’à 7,9 millions de dollars de l’IFLI pour soutenir le développement d’IPH6501 dans le lymphome folliculaireNASDAQ:IPHAInnate Pharma SA
06/12/202403:00Business WireInnate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) Announce up to $7.9M Investment From IFLI to Support IPH6501 Development in Follicular LymphomaNASDAQ:IPHAInnate Pharma SA
03/12/202403:00Business WireInnate Pharma partage les présentations sélectionnées pour le congrès annuel de l’ASH 2024NASDAQ:IPHAInnate Pharma SA
03/12/202403:00Business WireInnate Pharma Highlights Abstracts Selected for the ASH Annual Meeting 2024NASDAQ:IPHAInnate Pharma SA
20/11/202403:00Business WireInnate Pharma Releases Its 2025 Financial CalendarNASDAQ:IPHAInnate Pharma SA
20/11/202403:00Business WireInnate Pharma publie son calendrier financier pour 2025NASDAQ:IPHAInnate Pharma SA
19/11/202403:00Business WireInnate Pharma annonce une publication dans la revue Science Immunology mettant en avant le NK cell engager ANKET® de nouvelle génération IPH6501NASDAQ:IPHAInnate Pharma SA
19/11/202403:00Business WireInnate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET® IPH6501NASDAQ:IPHAInnate Pharma SA
13/11/202403:00Business WireInnate Pharma présente ses résultats financiers au troisième trimestre 2024NASDAQ:IPHAInnate Pharma SA
13/11/202403:00Business WireInnate Pharma Reports Third Quarter 2024 Business Update and Financial ResultsNASDAQ:IPHAInnate Pharma SA
08/11/202403:00Business WireInnate Pharma Highlights Data From Its Innovative Oncology Portfolio Selected for the SITC Annual Meeting 2024NASDAQ:IPHAInnate Pharma SA
08/11/202403:00Business WireInnate Pharma annonce les présentations de données de son portefeuille innovant en oncologie sélectionnées pour le congrès annuel du SITC 2024NASDAQ:IPHAInnate Pharma SA
07/11/202403:00Business WireInnate Pharma Announces Conference Call and Webcast for Third Quarter 2024 Results and Business UpdatesNASDAQ:IPHAInnate Pharma SA
07/11/202403:00Business WireInnate Pharma organise une conférence téléphonique pour ses résultats financiers et l’avancée de son portefeuille au troisième trimestre 2024NASDAQ:IPHAInnate Pharma SA
29/10/202403:00Business WireInnate Pharma annonce sa participation à de prochaines conférences investisseursNASDAQ:IPHAInnate Pharma SA
29/10/202403:00Business WireInnate Pharma Announces Its Participation in Upcoming Investor ConferencesNASDAQ:IPHAInnate Pharma SA
14/10/202402:00Business WireInnate Pharma Appoints Jonathan Dickinson as New Chief Executive Officer and Chairman of the Executive BoardNASDAQ:IPHAInnate Pharma SA
14/10/202402:00Business WireJonathan Dickinson est nommé Président du Directoire d’Innate PharmaNASDAQ:IPHAInnate Pharma SA
30/09/202402:00Business WireInnate Pharma to Host KOL Scientific Symposium on Immunotherapy in New York on October 3, 2024NASDAQ:IPHAInnate Pharma SA
30/09/202402:00Business WireInnate Pharma co-organise un symposium scientifique en présence d’experts de l’Immunotherapie à New York le 3 octobre 2024NASDAQ:IPHAInnate Pharma SA
23/09/202402:00Business WireInnate Pharma reçoit l’autorisation de l’agence américaine du médicament d’initier le développement clinique d’IPH4502, son ADC ciblant Nectine-4, dans les tumeurs solidesNASDAQ:IPHAInnate Pharma SA
23/09/202402:00Business WireInnate Pharma Announces FDA Clearance of the IND for IPH4502, a Nectin-4 ADC to Be Developed in Solid TumorsNASDAQ:IPHAInnate Pharma SA
12/09/202407:04IH Market NewsU.S. Index Futures Climb Ahead of Key Economic Data Releases; Oil Prices RiseNASDAQ:IPHAInnate Pharma SA
12/09/202402:00Business WireInnate Pharma Reports First Half 2024 Business Update and Financial ResultsNASDAQ:IPHAInnate Pharma SA
12/09/202402:00Business WireInnate Pharma présente l’avancée de son portefeuille et ses résultats financiers au premier semestre 2024NASDAQ:IPHAInnate Pharma SA
11/09/202417:00Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:IPHAInnate Pharma SA
09/09/202402:00Business WireInnate Pharma SA: Monalizumab Data From NeoCOAST-2 Phase 2 Study in Early-Stage NSCLC Presented at the WCLC 2024NASDAQ:IPHAInnate Pharma SA
 Apresentando as notícias mais relevantes sobre:NASDAQ:IPHA

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
SEQL3
Sequoia Logistica e Tran... ON
BOV
BRKM5
BRASKEM PNA
BOV
RAIZ4
Raizen S.A PN
BOV
TELB4
TELEBRAS PN
BOV
ATOM3
ATOMPAR ON
BOV
PRIO3
PETRORIO ON
BOV
RCSL4
RECRUSUL PN
BOV
PCAR3
PÃO DE AÇUCAR ON
BOV
AMBP3
Ambipar Participacoes e ... ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados